{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:08:38Z","timestamp":1778501318139,"version":"3.51.4"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbiological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.micres.2026.128511","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:35:38Z","timestamp":1775057738000},"page":"128511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-omics gut microbiome signatures for treat-to-target management in inflammatory bowel disease"],"prefix":"10.1016","volume":"309","author":[{"given":"Xiaoyu","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41746-024-01021-y","article-title":"Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA's De Novo pathway","volume":"7","author":"Aboy","year":"2024","journal-title":"NPJ Digit Med"},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib2","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2019.07.025","article-title":"Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases","volume":"157","author":"Aden","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther. Drug Monit."},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.cgh.2024.09.020","article-title":"Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease","volume":"23","author":"Alsoud","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib7","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20178124","article-title":"Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets","volume":"14","author":"Argelaguet","year":"2018","journal-title":"Mol. Syst. Biol."},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","article-title":"Biomarkers for Personalizing IBD Therapy: The Quest Continues","volume":"22","author":"Atreya","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib9","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000579","article-title":"Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities","volume":"14","author":"Bourgonje","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.cgh.2024.06.048","article-title":"AGA Clinical Practice Update on Endoscopic Scoring Systems in Inflammatory Bowel Disease: Commentary","volume":"22","author":"Buchner","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.micres.2026.128511_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jmsacl.2023.02.008","article-title":"The regulatory landscape of laboratory developed tests: Past, present, and a perspective on the future","volume":"28","author":"Budelier","year":"2023","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2023.11.304","article-title":"Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease","volume":"166","author":"Caenepeel","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3748\/wjg.v29.i10.1539","article-title":"Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies","volume":"29","author":"Cheah","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib15","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.micres.2026.128511_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.0461","article-title":"The Regulatory Landscape for Clinical Metagenomic Testing","author":"Chiu","year":"2025","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121577","article-title":"Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Paediatric Inflammatory Bowel Disease: A Real-World Study","volume":"16","author":"Clemente Bautista","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/gutjnl-2020-321106","article-title":"Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study","volume":"70","author":"Clooney","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jclinepi.2014.11.010","article-title":"Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"68","author":"Collins","year":"2015","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.micres.2026.128511_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"issue":"10114","key":"10.1016\/j.micres.2026.128511_bib21","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review","volume":"14","author":"Colombel","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2317932","article-title":"The intestinal microbiome of inflammatory bowel disease across the pediatric age range","volume":"16","author":"Conrad","year":"2024","journal-title":"Gut Microbes"},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nbt.3960","article-title":"Towards standards for human fecal sample processing in metagenomic studies","volume":"35","author":"Costea","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/apt.14173","article-title":"Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis","volume":"46","author":"Costello","year":"2017","journal-title":"Aliment Pharm. Ther."},{"issue":"10341","key":"10.1016\/j.micres.2026.128511_bib26","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jclinepi.2014.06.018","article-title":"A new framework to enhance the interpretation of external validation studies of clinical prediction models","volume":"68","author":"Debray","year":"2015","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjy190","article-title":"High-Throughput Identification of the Plasma Proteomic Signature of Inflammatory Bowel Disease","volume":"13","author":"Di Narzo","year":"2019","journal-title":"J. Crohns Colitis"},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.gastrohep.2022.10.019","article-title":"Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease","volume":"46","author":"Diaz","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apt.17622","article-title":"Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges","volume":"58","author":"Dignass","year":"2023","journal-title":"Aliment Pharm. Ther."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02120-17","article-title":"Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients","volume":"9","author":"Doherty","year":"2018","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib32","first-page":"621","article-title":"Remote Monitoring for Patients With Inflammatory Bowel Disease: Current Status and the Future of the Field","volume":"20","author":"Dong","year":"2024","journal-title":"Gastroenterol. Hepatol. (N. Y)"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2019.05.029","article-title":"Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease","volume":"18","author":"Dreesen","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib35","article-title":"Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease","volume":"60","author":"Dutt","year":"2024","journal-title":"Med. (Kaunas. )"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib36","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcph.1069","article-title":"Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System","volume":"58","author":"Eser","year":"2018","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.micres.2026.128511_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106845","article-title":"Exploring the interactions of JAK inhibitor and S1P receptor modulator drugs with the human gut microbiome: Implications for colonic drug delivery and inflammatory bowel disease","volume":"200","author":"Favaron","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat. Microbiol"},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib39","first-page":"840","article-title":"Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease","volume":"11","author":"Galtier","year":"2017","journal-title":"J. Crohns Colitis"},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib40","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1128\/JCM.00949-16","article-title":"Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories","volume":"54","author":"Gargis","year":"2016","journal-title":"J. Clin. Microbiol"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib41","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1038\/s41467-023-40156-6","article-title":"Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease","volume":"14","author":"Garrido-Trigo","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10151-025-03113-7","article-title":"Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials","volume":"29","author":"Gefen","year":"2025","journal-title":"Tech. Coloproctol."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67499-4","article-title":"Optimised human stool sample collection for multi-omic microbiota analysis","volume":"14","author":"Gemmell","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2023.09.019","article-title":"Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care","volume":"166","author":"Gilliland","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/gutjnl-2021-325185","article-title":"Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN","volume":"71","author":"Gorelik","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5858\/arpa.2023-0477-ED","article-title":"Navigating Next-Generation Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance","volume":"148","author":"Harada","year":"2024","journal-title":"Arch. Pathol. Lab Med"},{"issue":"9","key":"10.1016\/j.micres.2026.128511_bib47","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/ecco-jcc\/jjad213","article-title":"Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis","volume":"18","author":"Hassan-Zahraee","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib48","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.cgh.2017.06.007","article-title":"Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity","volume":"15","author":"Heida","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00431-023-05255-y","article-title":"Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting","volume":"183","author":"Hemming-Harlo","year":"2024","journal-title":"Eur. J. Pedia"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00069-18","article-title":"Evaluating the Information Content of Shallow Shotgun Metagenomics","volume":"3","author":"Hillmann","year":"2018","journal-title":"mSystems"},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib51","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ibd\/izad277","article-title":"Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort","volume":"30","author":"Hoelz","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib52","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41467-024-45855-2","article-title":"Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease","volume":"15","author":"Hu","year":"2024","journal-title":"Nat. Commun."},{"issue":"7662","key":"10.1016\/j.micres.2026.128511_bib53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature22969","article-title":"Fine-mapping inflammatory bowel disease loci to single-variant resolution","volume":"547","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.micres.2026.128511_bib55","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","article-title":"Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases","volume":"28","author":"Ianiro","year":"2022","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2016-312135","article-title":"Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease","volume":"67","author":"Imhann","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12876-018-0917-5","article-title":"The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1","volume":"19","author":"Imhann","year":"2019","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib58","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2036.2011.04857.x","article-title":"Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study","volume":"34","author":"Jakobsen","year":"2011","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.micres.2026.128511_bib60","article-title":"Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness","author":"Jang","year":"2024","journal-title":"bioRxiv"},{"issue":"10098","key":"10.1016\/j.micres.2026.128511_bib61","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","article-title":"Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial","volume":"390","author":"de Jong","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib62","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ecco-jcc\/jjac119","article-title":"Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease","volume":"17","author":"Joustra","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib63","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/ecco-jcc\/jjaa230","article-title":"Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease","volume":"15","author":"Kalla","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib64","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12866-023-03084-5","article-title":"Diagnosis of Crohn's disease and ulcerative colitis using the microbiome","volume":"23","author":"Kang","year":"2023","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.micres.2026.128511_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079830","article-title":"Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline","volume":"387","author":"Kawano-Dourado","year":"2024","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7351","key":"10.1016\/j.micres.2026.128511_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-014-0107-1","article-title":"Complex host genetics influence the microbiome in inflammatory bowel disease","volume":"6","author":"Knights","year":"2014","journal-title":"Genome Med"},{"key":"10.1016\/j.micres.2026.128511_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.784397","article-title":"Benchmark of Data Processing Methods and Machine Learning Models for Gut Microbiome-Based Diagnosis of Inflammatory Bowel Disease","volume":"13","author":"Kubinski","year":"2022","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chom.2024.05.022","article-title":"Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases","volume":"32","author":"Kumbhari","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"17","key":"10.1016\/j.micres.2026.128511_bib71","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3748\/wjg.v29.i17.2666","article-title":"Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial","volume":"29","author":"Lahtinen","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jcag\/gwac001","article-title":"Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective","volume":"5","author":"Lakatos","year":"2022","journal-title":"J. Can. Assoc. Gastroenterol."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib73","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"de Lange","year":"2017","journal-title":"Nat. Genet"},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib74","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1053\/j.gastro.2021.09.076","article-title":"Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last","volume":"162","author":"Le Berre","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.micres.2026.128511_bib75","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chom.2021.06.019","article-title":"Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease","volume":"29","author":"Lee","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib76","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1038\/s41467-022-33071-9","article-title":"Batch effects removal for microbiome data via conditional quantile regression","volume":"13","author":"Ling","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.micres.2026.128511_bib77","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/ecco-jcc\/jjae043","article-title":"Faecal Microbiota Transplantation Engraftment After Budesonide or Placebo in Patients With Active Ulcerative Colitis Using Pre-selected Donors: A Randomized Pilot Study","volume":"18","author":"van Lingen","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01457-23","article-title":"Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis","volume":"11","author":"Liu","year":"2023","journal-title":"Microbiol Spectr."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3748\/wjg.v29.i2.272","article-title":"Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology","volume":"29","author":"Liu","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"7758","key":"10.1016\/j.micres.2026.128511_bib80","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.micres.2026.128511_bib81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-018-0067-2","article-title":"FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine","volume":"3","author":"Luh","year":"2018","journal-title":"NPJ Genom. Med"},{"issue":"8","key":"10.1016\/j.micres.2026.128511_bib82","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/ecco-jcc\/jjw051","article-title":"Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition","volume":"10","author":"Magnusson","year":"2016","journal-title":"J. Crohns Colitis"},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib83","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/ecco-jcc\/jjaa010","article-title":"Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis","volume":"14","author":"Magro","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2287073","article-title":"Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review","volume":"15","author":"Meade","year":"2023","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib85","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/flgastro-2022-102309","article-title":"How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?","volume":"14","author":"Meade","year":"2023","journal-title":"Frontline Gastroenterol."},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11894-022-00854-5","article-title":"Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease","volume":"24","author":"Megna","year":"2022","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaa002","article-title":"Regulatory responses to medical machine learning","volume":"7","author":"Minssen","year":"2020","journal-title":"J. Law Biosci."},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib88","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41591-021-01552-x","article-title":"Reporting guidelines for human microbiome research: the STORMS checklist","volume":"27","author":"Mirzayi","year":"2021","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13073-022-01112-z","article-title":"Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease","volume":"14","author":"Mishra","year":"2022","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5009\/gnl220070","article-title":"De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease","volume":"17","author":"Miyatani","year":"2023","journal-title":"Gut Liver"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib91","first-page":"162","article-title":"Diagnostic tests: how to estimate the positive predictive value","volume":"2","author":"Molinaro","year":"2015","journal-title":"Neurooncol Pr."},{"key":"10.1016\/j.micres.2026.128511_bib92","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/IDR.S419243","article-title":"Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details","volume":"17","author":"Monday","year":"2024","journal-title":"Infect. Drug Resist"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib93","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Ann. Intern Med"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib94","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/j.cgh.2021.03.021","article-title":"A Systematic Review of Monogenic Inflammatory Bowel Disease","volume":"20","author":"Nambu","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib95","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40265-024-02115-3","article-title":"Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations","volume":"85","author":"Nielsen","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib96","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1038\/s41467-023-42788-0","article-title":"Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts","volume":"14","author":"Ning","year":"2023","journal-title":"Nat. Commun."},{"issue":"6464","key":"10.1016\/j.micres.2026.128511_bib97","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.aax2342","article-title":"Dissecting racial bias in an algorithm used to manage the health of populations","volume":"366","author":"Obermeyer","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.micres.2026.128511_bib98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12866-016-0708-5","article-title":"Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study","volume":"16","author":"Odamaki","year":"2016","journal-title":"BMC Microbiol"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib99","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365521.2020.1854342","article-title":"Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease","volume":"56","author":"Ostlund","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ibd\/izad103","article-title":"Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease","volume":"30","author":"Otten","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2356284","article-title":"Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis","volume":"16","author":"Pan","year":"2024","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib102","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cgh.2020.03.002","article-title":"Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases","volume":"19","author":"Papamichael","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib104","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","article-title":"Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases","volume":"45","author":"Papamichael","year":"2023","journal-title":"Ther. Drug Monit."},{"issue":"10075","key":"10.1016\/j.micres.2026.128511_bib105","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib106","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib107","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2309684","article-title":"A universe of human gut-derived bacterial prophages: unveiling the hidden viral players in intestinal microecology","volume":"16","author":"Pei","year":"2024","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MCG.0000000000001978","article-title":"Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease","volume":"59","author":"Petrov","year":"2025","journal-title":"J. Clin. Gastroenterol."},{"issue":"9","key":"10.1016\/j.micres.2026.128511_bib109","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib110","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib111","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.cell.2025.04.016","article-title":"The microbiome for clinicians","volume":"188","author":"Porcari","year":"2025","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.micres.2026.128511_bib112","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ibd\/izae231","article-title":"Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease","volume":"31","author":"Porth","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2391505","article-title":"Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease","volume":"16","author":"Prins","year":"2024","journal-title":"Gut Microbes"},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib114","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M18-1990","article-title":"Ensuring Fairness in Machine Learning to Advance Health Equity","volume":"169","author":"Rajkomar","year":"2018","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.micres.2026.128511_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104088","article-title":"Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis","volume":"81","author":"Rees","year":"2022","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib116","article-title":"Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations","volume":"6","author":"Ricart","year":"2024","journal-title":"Crohns Colitis 360"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib117","doi-asserted-by":"crossref","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","article-title":"Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis","volume":"27","author":"Rokkas","year":"2018","journal-title":"J. Gastrointestin Liver Dis."},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib118","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jpn3.12132","article-title":"Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease","volume":"78","author":"Rowland","year":"2024","journal-title":"J. Pedia Gastroenterol. Nutr."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib119","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.01105-20","article-title":"Dynamic Bayesian Networks for Integrating Multi-omics Time Series Microbiome Data","volume":"6","author":"Ruiz-Perez","year":"2021","journal-title":"mSystems"},{"issue":"18","key":"10.1016\/j.micres.2026.128511_bib120","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.micres.2026.128511_bib121","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"10383","key":"10.1016\/j.micres.2026.128511_bib122","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib123","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41564-017-0089-z","article-title":"Dynamics of metatranscription in the inflammatory bowel disease gut microbiome","volume":"3","author":"Schirmer","year":"2018","journal-title":"Nat. Microbiol"},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharm. Ther."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?","volume":"7","author":"Sharara","year":"2022","journal-title":"Inflamm. Intest Dis."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib127","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13073-016-0331-y","article-title":"Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease","volume":"8","author":"Shaw","year":"2016","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031206","article-title":"Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis","volume":"12","author":"Shi","year":"2023","journal-title":"J. Clin. Med"},{"issue":"17","key":"10.1016\/j.micres.2026.128511_bib129","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/bioinformatics\/bty1054","article-title":"DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays","volume":"35","author":"Singh","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.micres.2026.128511_bib130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13059-015-0841-8","article-title":"The microbiome quality control project: baseline study design and future directions","volume":"16","author":"Sinha","year":"2015","journal-title":"Genome Biol."},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib131","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nbt.3981","article-title":"Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium","volume":"35","author":"Sinha","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib132","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.chom.2020.01.021","article-title":"Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation","volume":"27","author":"Sinha","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib133","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.micres.2026.128511_bib134","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5009\/gnl240503","article-title":"Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study","volume":"19","author":"Song","year":"2025","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib135","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1038\/s41467-022-34405-3","article-title":"Faecal microbiome-based machine learning for multi-class disease diagnosis","volume":"13","author":"Su","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.micres.2026.128511_bib136","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ecco-jcc\/jjac027","article-title":"Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All","volume":"16","author":"Sudhakar","year":"2022","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.micres.2026.128511_bib137","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cpt.2831","article-title":"Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease","volume":"113","author":"Suleiman","year":"2023","journal-title":"Clin. Pharm. Ther."},{"issue":"23","key":"10.1016\/j.micres.2026.128511_bib138","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.micres.2026.128511_bib139","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ecco-jcc\/jjae084","article-title":"Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy","volume":"18","author":"Tamburini","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"10","key":"10.1016\/j.micres.2026.128511_bib140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/ecco-jcc\/jjac064","article-title":"Safety and Efficacy of an AIEC-targeted Bacteriophage Cocktail in a Mice Colitis Model","volume":"16","author":"Titecat","year":"2022","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib141","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib142","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s10620-023-08139-1","article-title":"Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA","volume":"69","author":"Valdes-Delgado","year":"2024","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib143","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0272989X14547233","article-title":"Calibration of risk prediction models: impact on decision-analytic performance","volume":"35","author":"Van Calster","year":"2015","journal-title":"Med Decis. Mak."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib144","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.micres.2026.128511_bib145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2105-7-91","article-title":"Bias in error estimation when using cross-validation for model selection","volume":"7","author":"Varma","year":"2006","journal-title":"BMC Bioinforma."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib146","article-title":"Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development","volume":"13","author":"Velikova","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"9","key":"10.1016\/j.micres.2026.128511_bib147","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf162","article-title":"Blood proteomic signatures associated with disease activity in inflammatory bowel diseases","volume":"19","author":"Veyssiere","year":"2025","journal-title":"J. Crohns Colitis"},{"issue":"472","key":"10.1016\/j.micres.2026.128511_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8914","article-title":"Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Vich Vila","year":"2018","journal-title":"Sci. Transl. Med"},{"issue":"8","key":"10.1016\/j.micres.2026.128511_bib149","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/gutjnl-2022-328048","article-title":"Faecal metabolome and its determinants in inflammatory bowel disease","volume":"72","author":"Vich Vila","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis. Mak."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib151","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MIB.0000000000000619","article-title":"Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease","volume":"22","author":"Vinding","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.micres.2026.128511_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2024.127660","article-title":"Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review","volume":"282","author":"Wang","year":"2024","journal-title":"Microbiol Res"},{"issue":"29","key":"10.1016\/j.micres.2026.128511_bib153","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","article-title":"Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review","volume":"29","author":"Wang","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.micres.2026.128511_bib154","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jsfa.13721","article-title":"Postbiotics in inflammatory bowel disease: efficacy, mechanism, and therapeutic implications","volume":"105","author":"Wang","year":"2025","journal-title":"J. Sci. Food Agric."},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib155","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/bib\/bbz105","article-title":"Managing batch effects in microbiome data","volume":"21","author":"Wang","year":"2020","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.micres.2026.128511_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2026.01.016","article-title":"Gut DNA virome enterotype dictates inflammation heterogeneity through tuning the phage-bacteria-sphingosine-intestine axis in Crohn's disease","author":"Wen","year":"2026","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.micres.2026.128511_bib157","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med"},{"key":"10.1016\/j.micres.2026.128511_bib158","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fcimb.2019.00002","article-title":"The Super-Donor Phenomenon in Fecal Microbiota Transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front Cell Infect. Microbiol"},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib159","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann. Intern Med"},{"issue":"6","key":"10.1016\/j.micres.2026.128511_bib160","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41666-020-00082-4","article-title":"Federated Learning for Healthcare Informatics","volume":"5","author":"Xu","year":"2021","journal-title":"J. Health Inf. Res"},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib162","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01516-24","article-title":"Variation in the metagenomic analysis of fecal microbiome composition calls for a standardized operating approach","volume":"12","author":"Xu","year":"2024","journal-title":"Microbiol Spectr."},{"issue":"1","key":"10.1016\/j.micres.2026.128511_bib163","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1038\/s41467-018-05357-4","article-title":"Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.micres.2026.128511_bib164","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41591-024-03280-4","article-title":"Noninvasive, microbiome-based diagnosis of inflammatory bowel disease","volume":"30","author":"Zheng","year":"2024","journal-title":"Nat. Med"}],"container-title":["Microbiological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944501326000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944501326000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:17:13Z","timestamp":1778498233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944501326000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":164,"alternative-id":["S0944501326000753"],"URL":"https:\/\/doi.org\/10.1016\/j.micres.2026.128511","relation":{},"ISSN":["0944-5013"],"issn-type":[{"value":"0944-5013","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-omics gut microbiome signatures for treat-to-target management in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Microbiological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micres.2026.128511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128511"}}